Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 141
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07583030 A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relaps… |
LVIVO-TaVec400 product | Myasthénie | Phase 1 | WITHDRAWN | En attente / non publié | Union Hospital, Tongji Medical Co… | China · Beijing Tiantan Hospital, Capital Medical Uni… | 2026-09-23 → 2026-09-23 | Ouvrir |
| NCT06987539 THYME — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Saf… |
Inebilizumab | Myasthénie | Phase 2 | RECRUITING | En attente / non publié | Amgen | United States, Argentina, Brazil, France, Italy, Pola… | 2026-07-21 → 2030-03-13 | Ouvrir |
| NCT06744920 RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability … |
Remibrutinib (Blinded) | Myasthénie | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States, Argentina, Australia, Brazil, Canada, … | 2025-02-07 → 2033-02-26 | Ouvrir |
| NCT07465289 MyVisionXT — A Study to Evaluate The Long-Term Safety And Efficacy of R… |
rozanolixizumab | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | UCB Biopharma SRL | United States, China, Japan, Spain · Mg0039 10103, Co… | 2026-09-16 → 2031-01-23 | Ouvrir |
| NCT07463521 MyVision — A Study to Evaluate the Efficacy and Safety of Rozanolixizum… |
rozanolixizumab | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | UCB Biopharma SRL | United States, Canada, China, Japan, Spain · Mg0038 1… | 2026-05-27 → 2029-01-22 | Ouvrir |
| NCT07673744 A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab … |
Ublituximab | Myasthénie | Phase 2 | RECRUITING | En attente / non publié | TG Therapeutics, Inc. | United States · TG Therapeutics Investigational Trial… | 2026-10-01 → 2030-01-01 | Ouvrir |
| NCT07818291 An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adult… |
EA5 | Myasthénie | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Shanghai Lanyi Therapeutics Co., … | China · Beijing Hospital, Beijing, China | Huashan Ho… | 2026-09-15 → 2027-12-31 | Ouvrir |
| NCT06392386 ADAPT Jr SC — A Study of Efgartigimod PH20 SC in Children Between 2 and… |
Efgartigimod PH20 SC | Myasthénie | Phase 2/3 | RECRUITING | En attente / non publié | argenx | United States, Australia, Belgium, Canada, Czechia, F… | 2024-06-28 → 2027-09 | Ouvrir |
| NCT05403541 Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induct… |
Batoclimab 680 mg SC weekly | Myasthénie | Phase 3 | TERMINATED | En attente / non publié | Immunovant Sciences GmbH | United States, Argentina, Brazil, Canada, Georgia, Ge… | 2022-06-27 → 2026-08-07 | Ouvrir |
| NCT05150210 SP Thoracic IDE Study |
Robotic-Assisted Surgery | Myasthénie | Non applicable | ACTIVE_NOT_RECRUITING | En attente / non publié | Intuitive Surgical | United States · Brigham and Women's Hospital, Boston,… | 2022-07-20 → 2028-07 | Ouvrir |
| NCT07596784 Efficacy and Safety of Ravulizumab in Chinese Adults Participants With … |
Ravulizumab | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | AstraZeneca | China · Research Site, Beijing, China | Research Site… | 2026-07-20 → 2027-08-17 | Ouvrir |
| NCT06704269 Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Ge… |
YTB323 | Myasthénie | Phase 1/2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States, France, Japan, United Kingdom · Housto… | 2025-04-22 → 2029-10-26 | Ouvrir |
| NCT06680037 A Study to Assess the Safety and Clinical Activity of Azer-cel in Parti… |
Azercabtagene zapreleucel (azer-c… | Myasthénie | Phase 1 | RECRUITING | En attente / non publié | TG Therapeutics, Inc. | United States · TG Therapeutics Investigational Trial… | 2025-05-06 → 2029-01-01 | Ouvrir |
| NCT07501702 ETNA — A Phase 2 Study to Evaluate Povetacicept in Adults With Generali… |
Povetacicept | Myasthénie | Phase 2 | RECRUITING | En attente / non publié | Vertex Pharmaceuticals Incorporat… | United States, Australia, Poland, Turkey (Türkiye), U… | 2026-05-13 → 2029-03-02 | Ouvrir |
| NCT07411963 EARLY-MG — Evaluation of the Condition of Patients Receiving EARLY Ravu… |
EARLY-MG — Evaluation of the Cond… | Myasthénie | À vérifier | RECRUITING | En attente / non publié | Centre Hospitalier Universitaire … | France · APHP, Le Kremlin-Bicêtre, France | CHU de la… | 2025-11-26 → 2027-06-01 | Ouvrir |
| NCT07215650 Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) |
Cizutamig | Myasthénie | Phase 1 | RECRUITING | En attente / non publié | Candid Therapeutics | China · Huashan Hospital affiliated to Fudan Universi… | 2025-09-16 → 2028-04 | Ouvrir |
| NCT07072988 OPTIMAGE — Evaluate the Benefit of Corticoid Sparing in Elderly With Ge… |
Efgartigimod | Myasthénie | Phase 4 | RECRUITING | En attente / non publié | Janssen Research & Development, L… | France · CHRU De Nancy, Nancy, France | CHU Charles N… | 2025-09-19 → 2027-10-01 | Ouvrir |
| NCT06799247 Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a P… |
Decartes-08 | Myasthénie | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Cartesian Therapeutics | United States, Canada, Italy, Poland, Serbia, Spain, … | 2025-05-06 → 2027-09-30 | Ouvrir |
| NCT04124965 A Study to Investigate the Long-term Safety, Tolerability, and Efficacy… |
rozanolixizumab | Myasthénie | Phase 3 | COMPLETED | En attente / non publié | UCB Biopharma SRL | United States, Canada, Czechia, Denmark, France, Germ… | 2019-10-29 → 2021-09-01 | Ouvrir |
| NCT03971422 A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patient… |
rozanolixizumab | Myasthénie | Phase 3 | COMPLETED | En attente / non publié | UCB Biopharma SRL | United States, Belgium, Canada, Czechia, Denmark, Fra… | 2019-06-03 → 2021-10-26 | Ouvrir |
| NCT04650854 A Study to Evaluate Rozanolixizumab in Study Participants With Generali… |
rozanolixizumab | Myasthénie | Phase 3 | COMPLETED | En attente / non publié | UCB Biopharma SRL | United States, Canada, Czechia, Denmark, France, Geor… | 2021-02-03 → 2024-01-25 | Ouvrir |
| NCT07787247 ROME-MG — Feasibility of Remote Monitoring of Patients With Myasthenia … |
ROME-MG — Feasibility of Remote M… | Myasthénie | À vérifier | RECRUITING | En attente / non publié | George Washington University | United States · The George Washington University, Was… | 2026-08-19 → 2028-10 | Ouvrir |
| NCT06158815 Investigation of the Effects of Proprioceptive Neuromuscular Facilitati… |
Investigation of the Effects of P… | Myasthénie | Non applicable | COMPLETED | En attente / non publié | Hacettepe University | Turkey (Türkiye) · Hacettepe University Faculty of Ph… | 2023-11-23 → 2024-12-25 | Ouvrir |
| NCT07217509 PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness … |
PPDTM CorEvitasTM Myasthenia Grav… | Myasthénie | À vérifier | ENROLLING_BY_INVITATION | En attente / non publié | CorEvitas | United States · CorEvitas, LLC, Waltham, United States | 2025-08-14 → 2099-12-31 | Ouvrir |
| NCT07215949 Zilucoplan for Severe gMG Exacerbations |
Zilucoplan® | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | Miriam Freimer | United States · The Ohio State University, Columbus, … | 2026-01-20 → 2028-04-01 | Ouvrir |